Lipid-Lowering Therapy Utilization and Dosage Among Patients with Acute Coronary Syndrome Events: A Retrospective Cohort from 12 Community Hospitals

被引:3
作者
Khatib, Rasha [1 ]
Yeh, Eric J. [2 ]
Glowacki, Nicole [1 ]
McGuiness, Catherine B. [3 ]
Xie, Handing [4 ]
Wade, Rolin L. [4 ]
Kalich, Bethany A. [5 ]
Li, Yi [6 ]
Rifai, Abdelhadi [7 ]
Sawlani, Neal [8 ]
机构
[1] Advocate Aurora Hlth, Advocate Aurora Res Inst, Acad Res & Strateg Partnership, 3075 Highland Pkwy,Suite 600, Downers Grove, IL 60515 USA
[2] Amgen Inc, Global Hlth Econ & Outcomes Res HEOR, Thousand Oaks, CA USA
[3] IQVIA, Hlth Econ & Outcomes Res, Real World Evidence, Wayne, PA USA
[4] IQVIA, Wayne, PA USA
[5] Amgen Inc, Thousand Oaks, CA USA
[6] IQVIA, R&D Solut, Bloomington, IL USA
[7] Cheyenne Reg Med Grp, Heart & Vasc Inst, Cheyenne, WY USA
[8] Advocate Lutheran Gen Hosp, Park Ridge, IL USA
关键词
lipid-lowering therapy; high-intensity statin; acute coronary syndrome; real-world data; prescribing; adherence; MYOCARDIAL-INFARCTION; UNITED-STATES; CHOLESTEROL; ADULTS; TRENDS; RISK;
D O I
10.2147/CLEP.S400903
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction: Clinical practice guidelines recommend initiating a high-intensity LLT and continued monitoring of low-density lipoprotein cholesterol (LDL-C) following acute coronary syndrome (ACS). We used real-world data to describe LLT utilization after discharge and 1-year adherence. The reduction in LDL-C was also evaluated.Methods: Data were extracted from electronic health records (EHRs) from 12 hospitals in a large community healthcare system in midwestern United States between 2013 and 2019. Data on eligible patients recently discharged with an ACS event were linked to pharmacy claims data to describe LLT fill rates and 1-year post-discharge adherence. Adherence was reported as the proportion of days covered >= 80%.Results: Of the 10,589 eligible patients, 49% filled a high-intensity statin at discharge and only 36% were adherent at 1 year. The mean (SD) age was 66.1 +/- 13.3, 39.3% were females, 58.8% were Caucasian, and 53.0% had Medicare. There was a clear trend for greater fill rates at discharge among patients with higher LDL-C values than those with lower values (p<0.01). Key predictors of high -intensity (versus medium-intensity) LLT use within 21 days after an ACS event included ACS type (odds ratio [OR] 0.59; 95% confidence interval [CI] 0.52-0.67 for NSTEMI versus STEMI), age group (OR: 0.59; 95% CI: 0.48-0.72 for >75 years versus <65 years), and statin use before index ACS event (OR: 1.56; 95% CI: 1.23-1.88).Conclusion: This real-world study found that despite recommendations in clinical practice guidelines, high-intensity LLT fill rates at discharge and 1-year adherence to LLT remain suboptimal. Clinical characteristics, including ACS type and LDL-C values, were strong predictors of filling and adherence to guideline-recommended therapy. Age, sex, and race/ethnicity disparities were observed in discharge fill rates and 1-year adherence. These results highlight the need for continued efforts at the patient and provider levels to improve LLT adherence among ACS patients.
引用
收藏
页码:547 / 557
页数:11
相关论文
共 50 条
[21]   Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome [J].
Huilian Tan ;
Ling Liu ;
Qinghou Zheng ;
Dahong Zhang ;
Qian Liu ;
Dong Cui ;
Lei Gao ;
Zhen Wang ;
Wen-Lei Wang ;
Jun Liu .
Advances in Therapy, 2021, 38 :3389-3398
[22]   Effects of Combined Lipid-Lowering Therapy on Low-Density Lipoprotein Cholesterol Variability and Cardiovascular Adverse Events in Patients with Acute Coronary Syndrome [J].
Tan, Huilian ;
Liu, Ling ;
Zheng, Qinghou ;
Zhang, Dahong ;
Liu, Qian ;
Cui, Dong ;
Gao, Lei ;
Wang, Zhen ;
Wang, Wen-Lei ;
Liu, Jun .
ADVANCES IN THERAPY, 2021, 38 (06) :3389-3398
[23]   The Association Between Time of Lipid-Lowering Therapy Initiation and Acute Clinical Presentation Among Patients Admitted With Coronary Artery Disease, and Its Effect on Future Cardiovascular Events: An Australian Observational Study [J].
Eccleston, David ;
Chowdhury, Enayet K. ;
Wang, Alex ;
Yeh, Eric J. ;
Rezkalla, Nevine ;
Kathe, Niranjan ;
Williamson, Anna E. ;
Schwarz, Nisha .
HEART LUNG AND CIRCULATION, 2025, 34 (02) :173-181
[24]   APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness [J].
Casillas-Munoz, Fidel ;
Valle, Yeminia ;
Francisco Munoz-Valle, Jose ;
Emilia Martinez-Fernandez, Diana ;
Lizet Reynoso-Villalpando, Gabriela ;
Enrique Flores-Salinas, Hector ;
Anais Llamas-Covarrubias, Mara ;
Ramon Padilla-Gutierrez, Jorge .
MEDICINA CLINICA, 2018, 151 (01) :1-7
[25]   Addition of Ezetimibe to Intensive Lipid-Lowering Therapy Is Associated With a Lower Incidence of Heart Failure in Patients With Acute Coronary Syndrome [J].
Yoshikawa, Masafumi ;
Honda, Atsushi ;
Arashi, Hiroyuki ;
Shibahashi, Eiji ;
Otsuki, Hisao ;
Kawada-Watanabe, Erisa ;
Ogawa, Hiroshi ;
Yamaguchi, Junichi ;
Hagiwara, Nobuhisa .
CIRCULATION JOURNAL, 2024, 88 (11) :1819-1824
[26]   Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome [J].
Yamashita, Satoshi ;
Sakamoto, Atsushi ;
Shoji, Satoshi ;
Kawaguchi, Yoshitaka ;
Wakabayashi, Yasushi ;
Matsunaga, Masaki ;
Suguro, Kiyohisa ;
Matsumoto, Yuji ;
Takase, Hiroyuki ;
Onodera, Tomoya ;
Tawarahara, Kei ;
Muto, Masahiro ;
Shirasaki, Yasutaka ;
Katoh, Hideki ;
Sano, Makoto ;
Suwa, Kenichiro ;
Naruse, Yoshihisa ;
Ohtani, Hayato ;
Saotome, Masao ;
Urushida, Tsuyoshi ;
Kohsaka, Shun ;
Okada, Eisaku ;
Maekawa, Yuichiro .
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (05)
[27]   Statin-ezetimibe versus statin lipid-lowering therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention [J].
Dai, Yun-Yan ;
Zhang, Hai-Shan ;
Zhang, Xin-Gang ;
Guan, Qi-Gang ;
Gao, Yuan ;
Li, Yu-Ze ;
Zhang, Yue-Lan ;
Jia, Da-Lin ;
Sun, Ying-Xian ;
Qi, Guo-Xian ;
Tian, Wen .
JOURNAL OF THORACIC DISEASE, 2017, 9 (05) :1345-1352
[28]   Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II [J].
Gitt, Anselm K. ;
Lautsch, Dominik ;
Ferrieres, Jean ;
De Ferrari, Gaetano M. ;
Vyas, Ami ;
Baxter, Carl A. ;
Bash, Lori D. ;
Ashton, Veronica ;
Horack, Martin ;
Almahmeed, Wael ;
Chiang, Fu-Tien ;
Poh, Kian Keong ;
Brudi, Philippe ;
Ambegaonkar, Baishali .
ATHEROSCLEROSIS, 2017, 266 :158-166
[29]   Reinforcing adherence to lipid-lowering therapy after an acute coronary syndrome: A pragmatic randomized controlled trial [J].
Zafeiropoulos, Stefanos ;
Farmakis, Ioannis ;
Kartas, Anastasios ;
Arvanitaki, Alexandra ;
Pagiantza, Areti ;
Boulmpou, Aristi ;
Tampaki, Athina ;
Kosmidis, Diamantis ;
Nevras, Vassileios ;
Markidis, Eleftherios ;
Papadimitriou, Ioannis ;
Vlachou, Anastasia ;
Arvanitakis, Konstantinos ;
Miyara, Santiago J. ;
Ziakas, Antonios ;
Molmenti, Ernesto P. ;
Kassimis, George ;
Zanos, Stavros ;
Karvounis, Haralambos ;
Giannakoulas, George .
ATHEROSCLEROSIS, 2021, 323 :37-43
[30]   Impact of an Intensive Lipid-Lowering Therapy Protocol on Achieving Target Low-Density Lipoprotein Cholesterol Levels in Patients With Acute Coronary Syndrome [J].
Seiyama, Kosuke ;
Oka, Akihiro ;
Miyoshi, Toru ;
Sudo, Yuya ;
Takagi, Wataru ;
Ugawa, Satoko ;
Okada, Tomoaki ;
Nosaka, Kazumasa ;
Doi, Masayuki .
CIRCULATION REPORTS, 2025, 7 (02) :131-138